Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

International, Practice-Based Recommendations for Prediction of Bleedings and Anti-Platelet/Anti-Coagulant (AP/AC) Co-Medications in CLL Patients Taking Ibrutinib

Evgeny Nikitin, MD, Jennifer Series, Aleksandr Poletaev, Mikhail Panteleev, PhD Dr.Sc, Prof., Georg Hopfinger, MD, Vadim Ptushkin, MD, Ulrich Jaeger, MD, Bernard Payrastre, PhD, Loic Ysebaert, MD PhD

Blood (2017) 130 (Supplement 1): 1711.

https://doi.org/10.1182/blood.V130.Suppl_1.1711.1711

Published: 2017

Journal Articles

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target.

Camille Fialin, Veronique De Mas, Stephane Manenti, Bernard Payrastre, PhD, Serge Roche, Christian Recher

Blood (2009) 114 (22): 994.

https://doi.org/10.1182/blood.V114.22.994.994

Published: 2009

Journal Articles

The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia.

Nathalie Gallay, PhD, Cédric Dos Santos, Lise Cuzin, MD, Marina Bousquet, Violaine Simonnet Gouy, Claire Chaussade, PhD, Michel Attal, MD, Bernard Payrastre, PhD, Cecile Demur, MD, Christian Recher, MD, PhD

Blood (2008) 112 (11): 1503.

https://doi.org/10.1182/blood.V112.11.1503.1503

Published: 2008

Journal Articles

Lyn Kinase Is Constitutively Activated, Controls the mTOR/p70S6K/4E-BP1 Pathway and Regulates Cell Proliferation in Acute Myeloid Leukemia.

Christian Recher, MD, Cedric Dos Santos, MD, Cecile Demur, MD, Valerie Bardet, MD,PhD, Nais Prade-Houdellier, Guy Laurent, MD,PhD, Bernard Payrastre, PhD

Blood (2006) 108 (11): 1946.

https://doi.org/10.1182/blood.V108.11.1946.1946

Published: 2006

Journal Articles

Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.

Christian Recher, MD, Odile Beyne-Rauzy, MD, Cecile Demur, MD, Françoise Huguet, MD, Guy Laurent, MD, Gaëtan Chicane, Cedric Dos Santos, Veronique Mansat-Demas, PhD, Bernard Payrastre, PhD

Blood (2004) 104 (11): 1791.

https://doi.org/10.1182/blood.V104.11.1791.1791

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

International, Practice-Based Recommendations for Prediction of Bleedings and Anti-Platelet/Anti-Coagulant (AP/AC) Co-Medications in CLL Patients Taking Ibrutinib

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target.

The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia.

Lyn Kinase Is Constitutively Activated, Controls the mTOR/p70S6K/4E-BP1 Pathway and Regulates Cell Proliferation in Acute Myeloid Leukemia.

Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

International, Practice-Based Recommendations for Prediction of Bleedings and Anti-Platelet/Anti-Coagulant (AP/AC) Co-Medications in CLL Patients Taking Ibrutinib

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target.

The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia.

Lyn Kinase Is Constitutively Activated, Controls the mTOR/p70S6K/4E-BP1 Pathway and Regulates Cell Proliferation in Acute Myeloid Leukemia.

Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only